[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 56, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Oxana  Polyakova Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 48, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Head of Innovation", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.18, "open": 1.16, "dayLow": 1.1, "dayHigh": 1.1955, "regularMarketPreviousClose": 1.18, "regularMarketOpen": 1.16, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.1955, "payoutRatio": 0.0, "beta": 0.451, "forwardPE": -0.5979381, "volume": 97794, "regularMarketVolume": 97794, "averageVolume": 416080, "averageVolume10days": 60680, "averageDailyVolume10Day": 60680, "bid": 0.8424, "ask": 1.42, "bidSize": 1, "askSize": 2, "marketCap": 30514148, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 3.57, "priceToSalesTrailing12Months": 2.5466657, "fiftyDayAverage": 1.15416, "twoHundredDayAverage": 1.521725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -40780856, "profitMargins": -2.0959802, "floatShares": 10141743, "sharesOutstanding": 26305300, "sharesShort": 191506, "sharesShortPriorMonth": 25121, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0073, "heldPercentInsiders": 0.4037, "heldPercentInstitutions": 0.38426998, "shortRatio": 0.16, "shortPercentOfFloat": 0.0119, "impliedSharesOutstanding": 26305300, "bookValue": 1.055, "priceToBook": 1.099526, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -25114000, "trailingEps": -0.94, "forwardEps": -1.94, "enterpriseToRevenue": -3.404, "enterpriseToEbitda": 1.61, "52WeekChange": -0.6067797, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 1.16, "targetHighPrice": 3.036615, "targetLowPrice": 1.0118395, "targetMeanPrice": 1.8566873, "targetMedianPrice": 1.5215962, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 76576000, "totalCashPerShare": 2.911, "ebitda": -25326000, "totalDebt": 5281000, "quickRatio": 4.253, "currentRatio": 4.404, "totalRevenue": 11982000, "debtToEquity": 19.034, "revenuePerShare": 0.447, "returnOnAssets": -0.17666, "returnOnEquity": -0.63492, "grossProfits": -12568000, "freeCashflow": -8559500, "operatingCashflow": -19544000, "revenueGrowth": 13.136, "grossMargins": -1.04891, "ebitdaMargins": -2.11367, "operatingMargins": -0.64048, "financialCurrency": "USD", "symbol": "LVTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1616765400000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.16, "postMarketChange": 0.0, "regularMarketChange": -0.01999998, "regularMarketDayRange": "1.1 - 1.1955", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 416080, "fiftyTwoWeekLowChange": 0.30999994, "fiftyTwoWeekLowChangePercent": 0.3647058, "fiftyTwoWeekRange": "0.85 - 3.57", "fiftyTwoWeekHighChange": -2.4099998, "fiftyTwoWeekHighChangePercent": -0.67507, "fiftyTwoWeekChangePercent": -60.67797, "earningsTimestamp": 1743161400, "earningsTimestampStart": 1747657800, "earningsTimestampEnd": 1748003400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.94, "epsForward": -1.94, "epsCurrentYear": -1.4355, "priceEpsCurrentYear": -0.8080808, "fiftyDayAverageChange": 0.005839944, "fiftyDayAverageChangePercent": 0.005059908, "twoHundredDayAverageChange": -0.3617251, "twoHundredDayAverageChangePercent": -0.23770726, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-25", "prevName": "Lava Therapeutics B.V.", "nameChangeDate": "2025-04-02", "averageAnalystRating": "2.5 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1743797105, "regularMarketTime": 1743796803, "exchange": "NMS", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.6949137, "regularMarketPrice": 1.16, "displayName": "LAVA Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]